Scalper1 News
In a week filled with earnings reports from big-cap biotechs, Gilead Sciences’ (GILD) might be the most watched as it reveals its first full quarter of sales for blockbuster hepatitis C drug Sovaldi. Gilead reports after the market close Tuesday. Overall, analysts polled by Thomson Reuters estimate that Gilead made 89 cents a share in Q1, up 85% from the year-earlier quarter. They estimate sales rose 55% to $3.9 billion. The main driver of that Scalper1 News
Scalper1 News